Aigen Investment Management LP Acquires 35,937 Shares of Pfizer Inc. (NYSE:PFE)

Aigen Investment Management LP increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 95.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,486 shares of the biopharmaceutical company's stock after acquiring an additional 35,937 shares during the quarter. Aigen Investment Management LP's holdings in Pfizer were worth $1,950,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the 4th quarter valued at approximately $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the 3rd quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective on the stock. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Guggenheim restated a "buy" rating and set a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.18 during trading hours on Wednesday, hitting $25.93. 37,049,759 shares of the stock were exchanged, compared to its average volume of 39,279,996. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company's 50 day moving average is $26.31 and its 200 day moving average is $27.27. The firm has a market capitalization of $146.93 billion, a P/E ratio of 18.39, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the firm earned $0.10 EPS. The business's revenue was up 24.7% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.63%. Pfizer's dividend payout ratio is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.